Drug intelligence / Profile preview

MRG006

Development stage: Preclinical
Lead developer: Lepu Biopharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MRG006 is an investigational therapeutic candidate being developed by Miracogen (Shanghai Miracogen Gene Technology Co., Ltd.). While specific details regarding its molecular target and modality have not been publicly disclosed in detail, Miracogen is a biotechnology company that primarily focuses on the development of next-generation antibody-drug conjugates (ADCs) for the treatment of various cancers. MRG006 is currently in the early stages of development, identified in company pipeline reports as being in the preclinical or early discovery phase.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on MRG006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRG006.

Explore the full profile